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Introduction 
While the gluten-free diet (GFD) is the best treatment for clinical gluten sensitivity (GS) (e.g. 
Celiac Disease; CD, Non-Celiac Gluten Sensitivity; NCGS), scientific opinion supports that 
gluten is safe for the general population[1]. However, celebrity/athletic endorsement of the 
GFD has cultivated an image of gluten as “unhealthy”[2].  
 “Lifestylers”, “free from” or “people who avoid gluten” are individuals who avoid gluten as 
a lifestyle choice. American market research[3] found that 44% of people buy gluten-free 
food for reasons other than GS, and that 65% believe that a GFD is generally healthier. This 
trend has driven the worldwide gluten-free industry from values of $1.7bn in 2011 to $3.5bn 
in 2016, and it is forecast to reach $4.7bn in 2020[4]. 
The surge in gluten-free popularity has also encouraged an opposing belief that it is a “fad” 
diet[2]. This is unfortunate for people with CD/NCGS who express that they are not taken 
seriously in restaurants, and even face dismissive attitudes from non-specialist clinicians[5]. 
The drawing of a clear line between those who do and do not benefit from a GFD is needed 
to ground public and clinical perspective on these issues. For this reason, we undertook the 
first double-blind randomised controlled trial (DRCT) of gluten (via gluten-containing flour) 
in healthy controls, hypothesising it would not cause any symptoms. 
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Methods 
Participants; Participants (who received no financial incentives), recruited by advertising, 
were ≥18 years, had no diagnosed gluten-related disorders and followed gluten-containing 
diets. The study aimed to recruit 30 subjects to divide into two groups; no previous data in 
healthy individuals is available but NCGS DRCTs have reported gastrointestinal symptom 
changes induced by gluten which would carry 89.2% power if observed within a group of 
N=15[6]. Subjects were serologically tested to detect CD. The trial was supported by 
personal research funds of Prof. Sanders, and sought ethical approval from the Yorkshire 
and Humber REC.  
Trial Design; Participants attended two study sessions at a community venue. Subjects were 
educated by a dietitian about a GFD and asked (with support) to commence a GFD for two 
weeks (Biagi score[7] measured GFD adherence). Subjects completed Gastrointestinal 
Symptom Rating Scales (GSRS[8]) to measure baseline abdominal pain, reflux, indigestion, 
diarrhoea and constipation. A visual analogue scale measured “Global fatigue”. 
Subjects were randomised by a study team member (double-blinded, parallel, 1:1 allocation 
in an “A-B-A-B” sequence) into two groups who received flour sachets labelled “A” or “B”, to 
add to their diet twice daily for two weeks while otherwise continuing their GFD. Flours 
(provided by Dutch Organic International Trade) contained either organic gluten (gluten 
group; 2x10g vital gluten sachets, daily, providing 14g gluten protein and 1.4 g starch 
carbohydrates), or a gluten-free blend (control group; rice, potato, tapioca, maize and 
buckwheat flour blend, 2x10g sachets daily). Finally, participants re-completed symptom 
measures and exited the DRCT.  
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Analysis; Variables were inspected for normality to determine appropriate analyses. Key 
variables were compared between randomised groups by frequency-based/groupwise 
testing to ensure baseline homogeneity. Primary/secondary outcomes examined change in 
symptom scores (follow-up minus baseline), compared between Gluten and Control groups 
by independent t-test. The primary outcome was change abdominal pain score. Post-hoc 
analyses compared symptom scores within groups using paired t-tests.  
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Results 
Consecutive recruitment commenced in December 2015 and closed in January 2016. 45 
people made contact before 30 were recruited. Reasons for not taking part included an 
unwillingness to commit to the dietary requirements/being unable to attend pre-specified 
study meeting dates. Serological CD testing excluded two from the study. The remaining 28 
subjects were randomised into the Gluten (N=14) and Control (N=14) groups and underwent 
the full trial, which ended in March 2016. No harms were reported. 
The overall group had a mean age of 38 years (range=19-63, SD=12), and was 75% female 
(N=21). Biagi score (which measured GFD adherence while participants otherwise consumed 
the study flours) was not different between groups (independent t-test p=0.834), while X2 
and independent t-tests/Mann-Whitney U showed no significant differences in any baseline 
characteristic (Table).  
Descriptively, mean symptom scores ubiquitously decreased in the Gluten group (implying 
symptomatic improvement). Individually, only one Gluten Group participant reported a 
worsening of some symptoms without improvement in others. Independent t-tests between 
randomised groups showed no significant differences in change of any symptom (abdominal 
pain: treatment/control mean(SD)=-0.36(1.95)/-0.29(1.49), p=0.914, partial ETA2=0.000, 
95% confidence interval=-1.42:1.28). See Table for full results. 
Post-hoc paired t-tests examining change in GSRS scores within-groups showed that the 
diarrhoea score significantly reduced in the Gluten group (baseline/follow-up mean(SD)= 
2.71(1.94)/1.64(0.92), p=0.033); this does not survive bonferroni correction. No other 
analyses were significant. 
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Discussion 
This is the first DRCT to demonstrate that consumption of gluten-containing flour does not 
generate symptoms in healthy volunteers. The trial measured how daily ingestion of the 
flour (containing 14g of gluten) affected a range of symptoms over two weeks, none of 
which significantly changed between groups. Within-group analyses similarly produced no 
significant findings, other than one indication that symptoms of diarrhoea improved in the 
Gluten group (likely anomalous and in any case does not support that the flour caused 
symptoms).  
Our results support the view that gluten does not appear to cause symptoms in individuals 
who do not have a physiological susceptibility to it (i.e. the majority of the population). As 
the GFD is not only thought to be no healthier than a “normal” diet, but has been suggested 
as overall sub-optimal[1], there is possibly clinical justification in actively discouraging 
people from starting it if they have no diagnosable sensitivity. 
A potential study limitation is the relatively short duration of the trial, although other DRCTs 
in NCGS indicate onset of symptoms can begin after one week[6]. Another consideration is 
that the study topic may have unintentionally attracted participants with NCGS/IBS, 
however the presence of these would likely bias the study towards positive findings so 
confidence in the null results should remain high. 
Patients who self-report symptoms related to gluten must have Celiac Disease and Non-
Celiac Gluten Sensitivity excluded, but on the basis of this new data perhaps the assertion by 
‘lifestylers’ that a GFD is beneficial can also be challenged.   
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Table. Summaries of key variables and analyses. Tests above the bold line show Mann-Whitney U / 
independent t-test / X
2
 analyses which compare study groups for homogeneity on baseline 
characteristics. Primary and secondary analyses are shown below the bold line, which compare 
change in symptom scores between study groups using independent t-tests. Partial ETA
2
 and 95% 
confidence intervals (CI) accompany these analyses to demonstrate effect size and precision.  
Variable 
Treatment 
Group (N=14) 
Control 
Group (N=14) 
p value 
Partial 
ETA
2
 
(95% CI) 
Sex; % female 78.6% 71.4% 
Baseline comparison  
p= 0.663 
- 
Age; mean(SD) 38.79(11.64) 37.57(13.32) 
Baseline comparison  
p= 0.799 
- 
Baseline (top) & 
Follow-up Abdominal 
Pain GSRS; mean(SD) 
2.50(1.40) 
2.14(1.70) 
2.36(1.34) 
2.07(1.00) 
Baseline comparison  
p= 0.721 
- 
Baseline (top) & 
Follow-up Reflux 
GSRS; mean(SD) 
1.71(1.14) 
1.64(1.15) 
2.50 (2.24) 
2.57(1.95) 
Baseline comparison  
p= 0.667 
- 
Baseline (top) & 
Follow-up Indigestion 
GSRS; mean(SD) 
2.14(1.35) 
2.07(1.33) 
2.14(1.35) 
1.79(0.98) 
Baseline comparison  
p= 0.946 
- 
Baseline (top) & 
Follow-up Diarrhoea 
GSRS; mean(SD) 
2.71(1.94) 
1.64(0.92) 
1.85(1.46) 
1.64(1.22) 
Baseline comparison  
p= 0.210 
- 
Baseline (top) & 
Follow-up 
Constipation GSRS; 
mean(SD) 
2.50(1.83) 
2.36(1.78) 
1.93(1.54) 
2.50(1.65) 
Baseline comparison  
p= 0.454 
- 
Baseline (top) & 
Follow-up Global 
Fatigue; mean(SD) 
6.64(2.37) 
6.64(2.79) 
6.57(2.44) 
5.57(2.21) 
Baseline comparison  
p= 0.839 
- 
Change in Abdominal 
Pain; mean(SD) 
-0.36(1.95) -0.29(1.49) 
Symptom change  
p= 0.914 
0.000 
(-1.42 : 
1.28) 
Change in Reflux; 
mean(SD) 
-0.07(0.73) +0.07(1.98) 
Symptom change  
p= 0.802 
0.002 
(-1.30 : 
1.02) 
Change in 
Indigestion; 
mean(SD) 
-0.07(1.69) -0.36(1.34) 
Symptom change  
p= 0.623 
0.009 
(-0.90 : 
1.47) 
Change in Diarrhoea; 
mean(SD) 
-1.07(1.69) -0.21(0.89) 
Symptom change  
p= 0.105 
0.098 
(-1.91 : 
0.19) 
Change in 
Constipation; 
mean(SD) 
-0.14(2.45) +0.57(1.51) 
Symptom change  
p= 0.360 
0.032 
(-2.29 : -
0.86) 
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Change in Fatigue; 
mean(SD) 
0.00(3.74) -1.00(3.60) 
Symptom change  
p= 0.477 
0.02 
(-1.85 : 
3.85) 
 
 
